Azienda Ospedaliero Univesitaria Ospedali Riuniti Umberto I- G.M. Lancisi- G. Salesi

Their core work

Azienda Ospedaliero Universitaria Ospedali Riuniti in Ancona is a major Italian university hospital complex combining clinical care with academic research. The institution brings together oncology, cardiology (Lancisi), and paediatrics (Salesi) under one roof, giving it a rare breadth of clinical departments. In H2020, they contributed as a clinical site provider — lending patient access, medical expertise, and hospital infrastructure to research consortia working on cancer immunotherapy and digital stroke rehabilitation. Their value to a consortium is direct patient contact and clinical validation, not laboratory research or technology development.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2016, so there is no meaningful temporal evolution to track — the institution entered EU research simultaneously in two quite different clinical areas: rare cancer immunotherapy and digital stroke rehabilitation. What the keyword contrast does reveal is a dual clinical identity: one grounded in oncology and experimental therapy (dendritic cells, mesothelioma), the other in rehabilitation medicine and patient-facing digital tools. Whether either direction has deepened since 2016 cannot be determined from the available data.

With only two projects both launched in 2016 and no subsequent EU activity visible in the data, it is unclear whether this hospital has continued in either direction — a potential collaborator should verify their current research programme directly.

How they like to work

This hospital has never led an H2020 project — it entered both projects as a supporting actor (once as participant, once as third party), which is typical for clinical institutions providing patient access rather than driving research agendas. The 21 consortium partners across 10 countries suggest the projects themselves were mid-to-large, but the hospital's own footprint within them was modest. Working with them likely means engaging a clinical department head to provide patient cohorts, clinical data, or protocol validation rather than a dedicated EU projects office.

Across two projects, the hospital has touched 21 unique partners in 10 countries — a breadth that reflects the consortium compositions of the projects they joined rather than their own networking activity. No geographic concentration is evident from the data.

What sets them apart

What sets this institution apart is its multi-speciality hospital structure — oncology, cardiology, and paediatrics under one organisational umbrella — which means a single consortium agreement can potentially access multiple clinical departments. For a consortium needing Italian clinical validation in oncology or neurology-rehabilitation, they offer a credible academic hospital in the Marche region, a geography less saturated with consortium partners than Milan or Rome. However, their EU research track record is thin, so a partner would need to assess their current research capacity directly.

Highlights from their portfolio

• MAGIC
  The only project where they received EC funding (EUR 158,043), focused on mobile-assisted stroke rehabilitation — an applied digital health use case with direct patient impact.
• H2020MM04
  Involvement in a dendritic-cell immunotherapy trial for malignant mesothelioma, a rare and aggressive cancer, signals access to specialist oncology clinical expertise even without direct EC funding.